647
Views
0
CrossRef citations to date
0
Altmetric
Clinical Research

Rivastigmine for the management of anticholinergic delirium

ORCID Icon, , ORCID Icon & ORCID Icon
Pages 82-87 | Received 16 Nov 2023, Accepted 09 Feb 2024, Published online: 11 Mar 2024

Figures & data

Table 1. Clinical characteristics and outcomes of 50 patients with anticholinergic delirium, who were treated by transdermal or oral rivastigmine.

Table 2. Anticholinergic agents ingested.

Figure 1. Sedation requirements in 50 patients after transdermal or oral rivastigmine administration for anticholinergic delirium.

Figure 1. Sedation requirements in 50 patients after transdermal or oral rivastigmine administration for anticholinergic delirium.

Table 3. Pharmacokinetic and pharmacokinetic properties of physostigmine and rivastigmine.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.